September #51 : A Load of Fit - by Lark Lands

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

NYPD Blue

Born to be Wild

Locked Up in Limbo

Amazing Grace

Chai Guy

Catching Up With...Ruby Amagwula

Desperately Seeking Separatists

Hack vs. Hacker

LA Snuff Film

Dole Banana Peel

Say What

Feel Like a Nuttall

Caps Are On

What Dubya Stands For

The Disability Dis

Emotional Rescue

The End of L’Affaire

Picks

Undetectablah

Mother Inferior

Not for Adults Only

Get Over It

Lipo Handles

Topic of Cancer

Success Sucks

A Load of Fit

Thanks for the Complement

A Loaded Question

Message in a Bottle

Regarding Henry

S.O.S.

Contributors

Source of a Different Color

Mom's Recipe

Three Penny Opera

Letters to the Editor September 1999

Say What!

Woody Cheers on Rx Marijuana

Feel Like a Nuttall

Digest This

Obits

Detectablues

Not for Adults Only

Success Sucks

Facts Behind the Fix



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

September 1999

A Load of Fit

by Lark Lands

The conventional wisdom is that drug-induced viral resistance is always evil—the leading cause of treatment failure. But a new Harvard University study offers tentative backing for the hope that treatment smartie Mike Barr first floated in these pages three years ago: that certain mutations may result in a weaker virus with a much-reduced ability to replicate. The researchers reported that the D30N mutation of the virus, which causes resistance to nelfinavir (Viracept), substantially reduced its replicative capability. The L90M mutation that confers resistance to saquinavir (Fortovase) resulted in a moderate decrease in viral fitness, while the mutations creating indinavir (Crixivan) resistance left the virus as fit as ever. Although cross-resistance among the meds has long been thought to make the second-choice drugs less effective in those previously PI-treated, changes in viral fitness may turn out to be a major factor. If these test-tube observations can be confirmed with viruses taken from PWAs whose drugs have failed, expect new and improved strategies about which drugs to take, and when.




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.